Search PubMed⌕ Search

Biomedical subjects

R L Ward

Publications and source records attributed to R L Ward.

195 records · Page 11Linked to original sources

The T 4 -free thyroxine index as a test of thyroid function of first choice.

The T(4)-free thyroxine index was used as the thyroid function test of first choice in a district general hospital for one year. Ninety-two patients were assessed both initially and at follow up by a single physician. The index agreed with clinical assessment in 69 out of 74 patients in whom diagnosis was unequivocal. There was initial doubt about thyroid status in 14 patients; after re-assessment the index agreed with status in seven cases, in three cases there is still some uncertainty, whilst the index was at variance with clinical status in four patients. Some possible causes of discrepancy between clinical thyroid status and the index are a low index in euthyroid patients due to a fall in serum thyroxine-binding prealbumin (;sick euthyroid'), a raised index in euthyroid patients due to latent thyroid heart disease, and a normal index in thyrotoxicosis due to preferential secretion of triiodothyronine.

Adult↗

Giving up smoking.

Explore the source record for details and available documents.

Adenocarcinoma↗

Checking the scoreboard: the impact of cancer genetics on clinical practice.

Improvements in cancer care have historically been predicated on significant scientific and technological advances, such as antisepsis in surgery, and the discovery of the therapeutic benefits of radiation and chemotherapeutic drugs. The past 30 years have seen an exponential increase in our knowledge of the biology and genetics of cancer, built on a massive and sustained research effort worldwide. Yet over the same period, significant changes in cancer outcomes have occurred largely as a result of public health measures and through incremental advances in existing technologies. The present paper examines the extent to which the new knowledge of cancer genetics has impacted on current patient care. It considers some of the issues that may have served to lessen this impact, as well as some of the reasons for this apparent imbalance between action and outcome.

Humans↗

Clinicopathological significance of erbB-2 expression in colorectal carcinoma.

The level of erbB-2 expression in both the tumour tissue and serum of individuals with colorectal carcinoma is unclear. This study aims to clarify expression levels and to relate these to a range of clinicopathological parameters. Overexpression of erbB-2 was detected in 25% of patient tumour tissue and an elevation in serum concentration of the extracellular domain (ECD) of erbB-2 was detected in 10% of patients. Surprisingly, an elevated serum ECD concentration did not correlate with erbB-2 overexpression within the primary tumour, and neither tumour or serum levels of the protein correlated with any clinicopathological parameters examined. These results indicate that erbB-2 overexpression in tissue and serum are not uncommon in colorectal carcinoma, but may not be useful as predictors of disease outcome.

Adult↗